Introduction Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human epidermal growth factor receptor 2 (HER2), a tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload. T-DXd, studied extensively in the DESTINY-Breast series (1–4), has shown promising results in managing both HER2-positive and HER2-low-expressing breast cancers, significantly impacting the treatment landscape.